An observational study in Respiratory Distress Syndrome, Newborn, sponsored by Keck School of Medicine of USC. Not yet recruiting at 1 site in United States. Open to participants aged 1 Hour to 24 Hours. Per ClinicalTrials.gov, last updated 2023-07-27.
Sponsored by Keck School of Medicine of USC · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Respiratory Distress Syndrome, Newborn with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Respiratory Distress Syndrome, Newborn · United States.
Among the 34 studies in Respiratory Distress Syndrome, Newborn with a site in United States, this one is one of 2 that started in 2023, is one of 5 observational ones, and was the 29th registered.
123 studies on the registry are indexed under Respiratory Distress Syndrome, Newborn; 24 are open to participants now.
Browse Respiratory Distress Syndrome, Newborn studies →5 of the 34 studies in Respiratory Distress Syndrome, Newborn with a site in United States are open now. Recruiting first, the newest first:
Hackensack Meridian Health · Sites in United States
Ages 27 wk–34 wk
Mayo Clinic · Sites in United States
Ages 32 wk–41 wk · Healthy volunteers
Connecticut Children's Medical Center · Sites in United States
Ages 0 hrs–2 hrs
Endeavor Health · Sites in United States
Ages up to 15 min · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Respiratory Distress Syndrome, Newborn studies recruiting now, 2 (17%) set no upper age limit and 10 (83%) stop at 75 or younger; 12 take children under 18; 2 take healthy volunteers.
This study: 1 Hour to 24 Hours · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 4 · Phase 4 5
First in 1995; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 150 across 25 observational studies indexed under Respiratory Distress Syndrome, Newborn.
Median enrollment 93 across the 29 interventional studies, 500 across the 5 observational. Of the 25 that completed or were terminated, 7 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 34 have an industry lead sponsor. The 10 most frequent:
Keck School of Medicine of USC is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Keck School of Medicine of USC has 2 studies filed under Respiratory Distress Syndrome, Newborn — fewer than ten, so there is no comparison to draw.
1 of the studies in Respiratory Distress Syndrome, Newborn with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06446453Connecticut Children's Medical CenterEchography-guided Surfactant THERapy (ESTHER) For Preterm Infants With Respiratory Failure | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 34 studies in Respiratory Distress Syndrome, Newborn with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Premature infants are more likely to develop hypoxemia after birth often requiring invasive and Non-Invasive Mechanical ventilation and surfactant therapy to improve alveolar gas exchange and oxygen transport. Near-infrared spectroscopy (NIRS) has been used to detect pulmonary regional oxygen saturation (rpSO 2 ) as well as cerebral regional oxygen saturation (rcSO2 ) and evaluate the oxygenation state of the lung and brain. This is a prospective observational study to evaluate utility of rpSO2 and compare it with rcSO2 in preterm infants born between 23-32 weeks of gestation receiving noninvasive ventilation and surfactant treatment. Enrolled patients will be continuously studied with placement of NIRS monitor using cerebral sensor (INVOS™) for 6 hrs and 15 min before and after surfactant administration. Pulmonary regional oxygen saturation (rpSO2) with a sampling interval of 6 s will be followed for 6hrs.
Inborn premature infants
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Infants born between 23-32 weeks of gestation admitted to the Neonatal Intensive Care Unit with respiratory distress receiving non-invasive ventilation and requiring Surfactant Replacement Therapy.
Exclusion Criteria:
Neonates with no need for respiratory support/Surfactant. Neonates with congenital malformations.
Premature infants will be studied with brain and lung NIRS before and after surfactant administration
rpSO2 before and after surfactant therapy
brain and lung rpSO2 will be compared before and after surfactant administration
Time frame: 6 hours
variations on rpSO2 and rcSO2 during changes in ventilation modes
Will evaluate for variations with various ventilation modes
Time frame: 6 hours
correlation between rpSO2L and SpO2/FiO2 ratio, a/APO2, and O.I
Correlation will be assessed between rpSO2 and other ratios
Time frame: 6 hours
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Aug 2023; primary completion for Jun 2024, 10 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome, Newborn →
Keck School of Medicine of USC